Chester County News and Community Website
NEWARK, DE — Corrixr Therapeutics appointed oncology drug-development executive Nancy Whiting as board chair as the preclinical genetic-medicine company prepares CXR101 for a regulatory filing and initial human testing in …
Corrixr Names Whiting Chair as CXR101 Nears Clinical Stage Read More NEWARK, DE — Corrixr Therapeutics has appointed biotechnology executive Hilary M. Malone as chief executive officer as the gene-editing company prepares to advance its lead cancer therapy candidate into regulatory …
Corrixr Therapeutics Names Malone CEO as Cancer Program Nears Clinical Testing Read More NEWARK, DE — New preclinical research from CorriXR Therapeutics suggests a novel gene-editing strategy could reopen the door to standard chemotherapy for patients whose cancers have become resistant to treatment, …
CRISPR Breakthrough Reverses Chemo Resistance in Aggressive Cancers Read More NEWARK, DE — CorriXR Therapeutics announced new peer-reviewed findings showing that its CRISPR-based gene-editing approach can resensitize squamous cell lung carcinoma (LUSC) tumors to standard chemotherapy, offering a potential path …
CRISPR Breakthrough Revives Chemo Response in Lung Cancer Models, CorriXR Reports Read More
NEWARK, DE — CorriXR Therapeutics, Inc. has secured a $1 million investment from the State of Delaware to accelerate its development of next-generation treatments for solid tumors, including head and …
CorriXR Secures $1M Investment to Advance Gene-Editing Cancer Therapies Read More